Improved Physical, Emotional, and Social Well-Being in People Living With Obesity Treated With Semaglutide: A Plain Language Summary
Therapeutic Advances in Endocrinology and Metabolism · 2026-03 · 17
DOI: 10.1177/20420188261437874 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Therapeutic Advances in Endocrinology and Metabolism, online erschienen am 30.04.2026. Verfasst von Ronette L Kolotkin und 3 weiteren Autor:innen. Beteiligte Einrichtung: Quality of Life Consulting, PLLC; Duke Family Medicine and Community Health, Duke University School of Medicine, Durham, North Carolina, USA. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Novo Nordisk A/S.
Abstract (Originalsprache)
What is this summary about? Many people live with extra weight or obesity. Semaglutide is a type of weight loss medication for the treatment of obesity. A study published in 2024 reported on the experiences of people taking semaglutide. People living with obesity who took semaglutide had improvements in their physical, emotional, and social health. Sharing the experiences of people taking weight loss medications may help others make important treatment decisions. What is the purpose of this plain language summary? Semaglutide is an approved medication for weight loss. In a recent study, people who lost weight while taking semaglutide had improved physical, mental, and social health. The goal of this summary is to share the study results in accessible language so that people living with obesity can make informed decisions about whether a medication for weight loss is right for them.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Quality of Life Consulting, PLLC; Duke Family Medicine and Community Health, Duke University School of Medicine, Durham, North Carolina, USA.
- Western Norway University of Applied Sciences, Førde, Norway; Morbid Obesity Centre, Vestfold Hospital Trust, Tønsberg, Norway.
- Novo Nordisk Service Centre India Private Ltd., Bangalore, India.
- Novo Nordisk, Søborg, Denmark.
Förderung
- Novo Nordisk A/S
Zitieren
APA
Kolotkin, R. L., K, R., Brandi, H., & Hahn-Pedersen, J. H. (2026). Improved Physical, Emotional, and Social Well-Being in People Living With Obesity Treated With Semaglutide: A Plain Language Summary. Therapeutic Advances in Endocrinology and Metabolism, 17. https://doi.org/10.1177/20420188261437874
Vancouver
Kolotkin RL, K R, Brandi H, Hahn-Pedersen JH. Improved Physical, Emotional, and Social Well-Being in People Living With Obesity Treated With Semaglutide: A Plain Language Summary. Therapeutic Advances in Endocrinology and Metabolism. 2026;17. doi:10.1177/20420188261437874
BibTeX
@article{Kolotkin2026,
author = {Kolotkin, Ronette L and K, Rajitha and Brandi, Henrik and Hahn-Pedersen, Julie Hviid},
title = {Improved Physical, Emotional, and Social Well-Being in People Living With Obesity Treated With Semaglutide: A Plain Language Summary},
journal = {Therapeutic Advances in Endocrinology and Metabolism},
year = {2026},
volume = {17},
doi = {10.1177/20420188261437874}
}
EUVIMED